Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13), Zacks reports.
Alpha Tau Medical Trading Up 2.3 %
Alpha Tau Medical stock traded up $0.06 on Wednesday, hitting $2.66. 18,824 shares of the stock traded hands, compared to its average volume of 48,834. Alpha Tau Medical has a 1 year low of $1.75 and a 1 year high of $4.39. The firm has a market cap of $186.00 million, a P/E ratio of -6.19 and a beta of 0.87. The business’s fifty day simple moving average is $3.30 and its 200 day simple moving average is $2.78.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Alpha Tau Medical in a report on Friday, November 22nd.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Featured Articles
- Five stocks we like better than Alpha Tau Medical
- What is a Low P/E Ratio and What Does it Tell Investors?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Airline Stocks – Top Airline Stocks to Buy Now
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Stock Splits, Do They Really Impact Investors?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
